Study drugs for blood-vessel Behçet’s to reduce inflammation
Treatments studied
Part of Eyes & vision, Genetic & congenital, Heart & circulation, Mouth & dental, Skin clinical trials.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign the consent form before any study procedures.
- You’re 18 to 65 years old.
- You meet established criteria for Behçet’s disease.
- Your aorta and/or leg/arm arteries have an aneurysm or bulging area confirmed by ultrasound or CT angiography.
- Your blood tests show high inflammation markers (ESR and hs-CRP).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests infliximab, a medicine that calms inflammation, for dolichoectactic aneurysms in the vertebral/basilar brain blood vessels that usually cannot be treated with standard surgery or procedures. The goal is to see if it can improve safety and how the aneurysm behaves over time.
This study tests a new pill called Hemay005 for adults with Behçet's disease who have at least two mouth sores that need treatment beyond creams or rinses. It aims to see if the drug safely reduces mouth ulcers.
This trial tests baricitinib, an oral medication, for people with intestinal Behçet's disease that hasn't improved with standard treatments. It aims to see if baricitinib can reduce symptoms and help heal gut ulcers.
This trial tests whether adding a blood thinner (anticoagulant) to steroid therapy is more effective than steroids alone for treating deep vein thrombosis (a blood clot in a large vein) in people with Behçet's syndrome. It aims to find the best way to prevent future clots and reduce side effects.
This study compares two medicines—adalimumab and tocilizumab—to see which works better and is safer for severe “uveitis” in people with Behçet’s disease. It’s meant for adults whose eye inflammation threatens their sight.
This trial compares standard immunosuppressive therapy alone versus adding a blood thinner (rivaroxaban) for treating newly diagnosed blood clots in the legs of people with Behcet's disease. It aims to see if adding the anticoagulant improves clot resolution without increasing bleeding risk.
Hear when a new Aneurysm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.